An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Niraparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors TESARO
- 09 Mar 2018 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
- 09 Mar 2018 Planned primary completion date changed from 1 Dec 2018 to 1 May 2019.
- 08 Feb 2018 Status changed from not yet recruiting to recruiting.